Search Result for : Generic Drugs

Sneha Gilada The pharma bigwigs, after the government recently imposed a cap on stent prices, are in for another rough ride as PM Modi seeks to make prescription of cheap generic drugs binding on doctors. Speaking at the inauguration ceremony of a charitable hospital in Surat on April 17, Narendra Modi vowed to take on the mantle of making healthcare affordable to the Indian middle class and poor. In his speech, he averred that the health policy was being revamped after a gap of 15 years. The last time it was updated was back in 2002. The new health policy lays special emphasis on the pricing of drugs included in the National List of Essential Medicines (NLEM), along with the timely revision of the list. "Price control ...

Sneha Gilada Bio Asia 2017, a global healthcare exhibition and conference, started on February 6, 2017, here in  Hyderabad. The three day event was inaugurated by the Telangana Governor ESL Narsimhan. Early into the second day of Bio Asia, packed halls witnessed eminent speakers from the pharma industry sharing their future vision for the global healthcare sector. The 14th edition of Bio Asia, as the theme suggests, was a platform for delegates, coming from more than 50 countries, to collaborate and leverage India's potential in achieving quality healthcare for billions all over the world. Dr. Paul Stoffels, Worldwide Chairman of Pharma, Johnson & Johnson(J&J) The must-attend event for any healthcare enthusiast saw participation from more than 800 corporates, and over 100 high-profile speakers. The morning session on February 7 had a special address from the likes of  Dr. Paul Stoffels, Worldwide Chairman ...

The Dollar Business Bureau World Trade Organisation (WTO) has finalised a deal that allows poor countries, which do not have manufacturing infrastructure for the production of generic drugs, to import the same. The proposal has been awaiting approval since 2005. It finally got ratified by two-thirds majority on 23 January, 2017. "The amendment to the Trade Related Aspects of Intellectual Property (TRIPS) agreement gives the world's most vulnerable people access to drugs for diseases such as HIV/AIDS, tuberculosis and malaria," WTO Director General Roberto Azevedo said. Countries are permitted to produce generic versions of patented drugs for their domestic markets since the beginning of WTO regime in 1995. Only in 2003 were the poor countries given a temporary waiver to import these drugs. Ever since, it has been renewed every two years until ...

The Dollar Business Bureau As the new European Union trademark law has been passed without considering any of the suggestions India has made, now the country is weighing its options in case the EU seizes its pharmaceutical exports to the third world countries. According to a source from Commerce Ministry, the country will not hesitate to knock the doors of World Trade Organization. It is pursuing the issue bilaterally as it does not want any uncertainty. He also said that the EU is ready to discuss the matter with India to have a broader dialogue on Intellectual Property Rights. As per the stringent enforcement provisions of new trademark legislation, customs officials can seize international consignments destined to third countries if they have brand ...

Source: PTI  India and the European Union will hold their long-pending summit in the first half of next year and resume negotiations on a free trade agreement, in efforts to bring back the relationship back on track. Newly-appointed ambassador of European Union Tomasz Kozlowski said the issue of European Union restricting sale of around 700 generic drugs clinically tested by India's GVK Biosciences does not stand anymore and both are now set to open a “new page” in their ties. FTA talks between the two sides will be held in January. “The summit meeting will be held in first half of 2016. We are now working on mutually convenient dates for the summit,” he told reporters while describing India an engine ...

The Dollar Business Bureau India’s generic drug market is expected to cross $27.9 billion and would account for 85% share in the domestic drug market by 2020, according to a study undertaken by ASSOCHAM and RNCOS. The current generic market size is $13.1 billion and is growing at a CAGR of about 16.3%, primarily due to approval granted by the USFDA makers and 21 drugs patent losing licenses by 2019, the study said. “Generic drugs account for 75% of the domestic pharmaceutical market by value. Drugs for cholesterol control, pain management, anticoagulant, respiratory, liver disorders, depression and lipid regulators are highly prevalent in the global market,” said the Associated Chambers of Commerce and Industry of India (ASSOCHAM) and RNCOS. The study was conducted on ‘Generic ...